Basic Hygroton Information

• INN (International Nonproprietary Name): Chlorthalidone
• Brand Names Available In United Kingdom: Hygroton (global), generic chlorthalidone formulations; specific UK-branded listings not specified
• ATC Code: C03BA04
• Forms & Dosages: Tablets 12.5 mg, 25 mg, 50 mg, 100 mg; no non-oral forms specified
• Manufacturers In United Kingdom: Not specified (global manufacturers include Novartis, Apotex and others)
• Registration Status In United Kingdom: Not specified (approved by EMA and listed in other European registrations)
• OTC / Rx Classification: Prescription Only (Rx)

Latest Research Highlights (UK & EU, 2022–2025)

Worried about overnight or early-morning blood pressure spikes and whether a thiazide-like option helps?

Recent UK and EU meta-analyses and large NHS-linked cohort studies reported that chlorthalidone has a longer half-life than short-acting thiazides and provides superior 24-hour blood-pressure coverage.

Those analyses noted modest improvements in systolic blood pressure reduction in primary hypertension when compared with hydrochlorothiazide.

European pharmacoepidemiology reports highlighted that once-daily dosing can improve adherence, especially in older adults, but also reported higher rates of hypokalaemia in elderly cohorts.

The MHRA and EMA post-marketing surveillance between 2022 and 2025 identified Yellow Card reports linking severe electrolyte disturbances to higher chlorthalidone doses and to co-prescribing with ACE inhibitors or loop diuretics.

The regulatory signal strength was described as moderate but actionable, prompting guidance on closer serum electrolyte monitoring.

Randomised comparisons across EU centres suggested that, when doses are adjusted, chlorthalidone and indapamide appear broadly equivalent for cardiovascular outcomes, though head-to-head large RCTs remain limited.

Health-economics evaluations in UK settings generally favour chlorthalidone for patients needing sustained nocturnal blood-pressure control due to once-daily regimens, with monitoring costs offsetting some savings.

Data Highlight: MHRA and EMA Yellow Card reports (2022–2025) showed a moderate signal for severe electrolyte disturbance associated with higher chlorthalidone doses and co-prescribing with ACE inhibitors or loop diuretics.

Clinical Effectiveness In The UK (NHS Outcomes)

How does Hygroton perform in everyday NHS practice compared with standard thiazides?

NHS practice audits and primary-care database analyses show sustained blood-pressure reductions with chlorthalidone and improved overnight coverage compared with short-acting thiazides.

Clinic-measured systolic blood pressure trends typically show modest reductions and fewer early-morning surges with chlorthalidone in patients with primary hypertension.

Patient-reported outcome measures collected via NHS patient portals indicate better adherence for many patients because chlorthalidone is once daily.

Higher frequency of clinic visits for serum electrolyte checks is reported, usually arranged by the GP or practice nurse following local NHS protocols.

NHS outcome datasets emphasise effectiveness in isolated systolic hypertension and as part of combination therapy, with reduced effect in advanced renal impairment.

Standard safety monitoring in primary care includes serum sodium, potassium and creatinine testing at baseline and during follow-up.

• BP Control Rates: Improved 24-hour control versus short-acting thiazides.
• Adherence: Higher with once-daily dosing, reported in NHS portal feedback.
• Monitoring Visits: Increased blood-test appointments for electrolytes, commonly 1–2 weeks after initiation then periodically.

Indications & Expanded Uses (MHRA-Approved And Off-Label)

Are you wondering what Hygroton is approved for and when clinicians might use it off-label?

MHRA and EMA-aligned indications classify chlorthalidone as a thiazide-like diuretic for antihypertensive therapy and for management of oedema.

Typical MHRA-label dosing for hypertension starts at 12.5–25 mg once daily with a usual maximum of 50 mg/day.

Edema dosing can be higher and individualised, with reported ranges up to 100 mg once daily where needed.

Off-label uses in UK specialist practice include targeting nocturnal hypertension, using chlorthalidone as an adjunct in resistant hypertension and low-dose combinations aimed at stroke prevention when managed by a cardiologist or nephrologist.

Paediatric use is generally avoided unless under specialist supervision because safety and efficacy have not been established.

Note: Chlorthalidone is a prescription-only medicine and initiation requires a prescriber with scheduled NHS follow-up.

Composition & Brand Landscape (UK Focus)

Which brands and dosages will a pharmacist or patient typically see on the shelf?

The active ingredient is chlorthalidone (INN).

Global brand Hygroton is listed in the raw product data and generic chlorthalidone tablets are supplied by multiple manufacturers including Novartis and Apotex.

Common dosages widely available are 12.5 mg, 25 mg and 50 mg tablets, with 100 mg less commonly used in primary care.

Packaging is usually blister strips or bottles and labelling can vary slightly between suppliers.

Pharmacy supply patterns differ by chain and wholesaler, with Boots, LloydsPharmacy and Superdrug commonly stocking 25 mg tablets as standard.

API sourcing is often from EU, India or Korea according to supplier data.

Storage guidance is to keep tablets at 15–25°C away from moisture and light.

Contraindications & Special Precautions (UK Clinical Safety)

What should patients and prescribers worry about before starting Hygroton?

Absolute contraindications include anuria, severe renal failure, known hypersensitivity to chlorthalidone or sulfonamide-derived drugs and refractory hypokalaemia or hypercalcaemia.

Relative contraindications requiring monitoring include gout, diabetes mellitus, electrolyte imbalance, pregnancy and breastfeeding unless benefits outweigh risks, and hepatic disease.

Elderly patients are at higher risk of hypokalaemia and generally should start at the lower dose of 12.5 mg daily with close monitoring.

Advise patients about orthostatic hypotension and the possible effect on driving or operating machinery until individual tolerance is known.

Alcohol can exacerbate hypotensive effects and patients should be counselled to moderate intake.

Prescriber Checklist

• Baseline serum Na+, K+, creatinine prior to initiation.
• Repeat labs 1–2 weeks after initiation or dose change, then periodically.
• Consider dose reduction or specialist referral for eGFR <30 mL/min/1.73m2.

Dosage Guidelines (NHS-Aligned Regimens)

How should Hygroton be started and titrated in routine NHS care?

For hypertension, usual starting dose is 12.5–25 mg once daily with a typical maximum of 50 mg/day for blood-pressure control.

For oedema the dose is individualised, commonly between 25 and 100 mg once daily depending on response.

Elderly patients should start at the lower end, for example 12.5 mg once daily, with close potassium and sodium monitoring.

In renal impairment efficacy falls and the risk of adverse effects rises, so dose reduction or avoidance is advised in severe impairment and nephrology input is recommended.

If a dose is missed, take the tablet as soon as remembered unless it is near the time of the next dose; do not double the dose.

Overdose is managed with supportive care and monitoring for hypokalaemia, hyponatraemia, dehydration and hypotension.

Interactions Overview (Drugs, Food, Reporting)

Which medicines and foods interact with chlorthalidone and what should be reported?

Co-prescription with loop diuretics, corticosteroids or amphotericin increases the risk of hypokalaemia and requires monitoring.

ACE inhibitors or ARBs can predispose to electrolyte abnormalities when combined with chlorthalidone, so serum potassium and renal function should be checked regularly.

NSAIDs may blunt antihypertensive response and raise renal risk when used with chlorthalidone.

Thiazide-like diuretics can increase lithium levels; therapeutic drug monitoring of lithium is necessary if used together.

High-salt diets may reduce efficacy, and potassium-rich diets can help mitigate hypokalaemia but do not replace biochemical monitoring.

If you suspect an adverse drug reaction related to chlorthalidone, report it via the MHRA Yellow Card scheme.

Cultural Perceptions & Patient Habits (UK Patient Centred)

What do UK patients say when they start a new diuretic like Hygroton?

Patient forums and NHS surveys show many people value once-daily medicine and trust pharmacist counselling for new antihypertensives.

Common concerns raised by patients include the frequency of blood tests and the possibility of gout or fluid-loss symptoms such as cramps.

Regional differences exist; Scottish and Welsh patients often use NHS direct services and local health boards for monitoring.

Some English patients use private clinics or online pharmacies for faster appointments and prescription renewals.

Community pharmacist interventions, including medicine use reviews and counselling on side effects, are culturally expected and help adherence.

Electronic Prescription Service (EPS) uptake and online pharmacy use are growing across the United Kingdom.

Availability & Pricing Patterns (Boots, Lloyds, NHS)

How easy is it to get Hygroton on the NHS or privately in the UK?

Hygroton and generic chlorthalidone are prescription-only and stocked variably by Boots, LloydsPharmacy and Superdrug, depending on local wholesaler availability.

In England patients normally pay the standard NHS prescription charge unless exempt, while Scotland, Wales and Northern Ireland have abolished routine prescription charges.

Private purchase prices vary by brand and pack size, and online pharmacies will typically offer a monthly supply after prescription validation.

Occasional API supply delays reported in trade publications can affect local stock and pack sizes.

In our online pharmacy, hygroton is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

Comparable Medicines And Prescribing Preferences (NHS Alternatives)

Which drugs do GPs choose instead of chlorthalidone and why?

Common NHS alternatives include hydrochlorothiazide, indapamide and bendroflumethiazide.

Hydrochlorothiazide has a shorter half-life and is generally considered less potent for 24-hour control.

Indapamide is another thiazide-like option and is favoured by some prescribers for renal-protection evidence in certain contexts.

Choice depends on desired 24-hour efficacy, side-effect risk (notably hypokalaemia and hyperuricaemia), comorbidities such as gout or diabetes, monitoring capacity and cost.

Where monitoring is impractical, indapamide may be preferred by some NHS clinicians.

When switching between diuretics, clinicians generally cross-titrate and check electrolytes soon after the change to avoid disturbance.

FAQ (Common NHS Patient Questions)

1. Will Hygroton make me need more blood tests?

Yes — baseline and periodic serum sodium, potassium and creatinine tests are standard when starting chlorthalidone.

2. Can I drive while taking Hygroton?

Most patients can drive, but caution is advised if dizziness or orthostatic symptoms develop; report any problems to your prescriber.

3. Can I take Hygroton with my other heart drugs?

Many combinations are safe but ACE inhibitors, ARBs, lithium and NSAIDs need particular monitoring — always tell your prescriber and pharmacist about all medicines.

4. Is it available on the NHS?

Yes — chlorthalidone is a prescription-only medicine and may be prescribed on the NHS, though local formularies and preferences vary by health board or CCG.

For patient leaflets and how to report side effects, see NHS patient information and the MHRA Yellow Card guidance.

Guidelines For Proper Use (Pharmacist Counselling & NHS Support)

What should a pharmacist say when handing out a new prescription for Hygroton?

Confirm the indication for use and review baseline laboratory tests before supply.

Advise once-daily morning dosing to reduce nocturia unless the prescriber has asked for nocturnal dosing to target night-time blood pressure.

Warn about dizziness and orthostatic hypotension and recommend getting up slowly from sitting or lying positions.

Advise moderation of alcohol and to report muscle cramps, palpitations or signs of dehydration immediately.

Provide written medicine information and signpost to NHS 111, the NHS patient portal and the MHRA Yellow Card for adverse event reporting.

Community pharmacists should schedule adherence checks and ensure blood tests are arranged 1–2 weeks after initiation and periodically thereafter.

Pharmacist Counselling Script (Short)

• "This tablet is chlorthalidone, often sold as Hygroton. Take one tablet each morning unless told otherwise."
• "Please book a blood test with your GP for sodium, potassium and kidney function in 1–2 weeks."
• "If you feel dizzy, stop driving and tell your prescriber."

Delivery Across United Kingdom